Company profile: Eidos Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage biotechnology research and development of novel, genetically targeted therapies to improve the lives of patients.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eidos Therapeutics
Artelo Biosciences
HQ: United States
Website
- Description: Provider of endocannabinoid system modulating therapeutics, including ART27.13, a synthetic dual CB1/CB2 GPCR agonist intended to increase appetite and reduce muscle wasting; ART26.12, a selective fatty acid binding protein inhibitor with potential in cancer and chemotherapy-induced peripheral neuropathy; and ART12.11, a proprietary cannabidiol–tetramethylpyrazine cocrystal designed to improve CBD's pharmaceutical properties.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artelo Biosciences company profile →
Spexis
HQ: Switzerland
Website
- Description: Provider of macrocycle drug discovery and development addressing high unmet medical needs, offering ColiFin (EU-approved inhaled therapy for chronic infections in cystic fibrosis, seeking U.S. approval); inhaled murepavadin for Pseudomonas aeruginosa infections; balixafortide, a macrocyclic CXCR4 inhibitor; and Macrocycle and OMPTA platforms for rare diseases and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spexis company profile →
Forge Biologics
HQ: United States
Website
- Description: Provider of end-to-end AAV gene therapy manufacturing and development services from preclinical to commercial stages, including plasmid DNA production (research-grade to cGMP), turnkey research-grade AAV via Blaze Vector Production using proprietary Ignition Cells, process and analytical development, cGMP production in 50L to 5,000L bioreactors, integrated regulatory solutions, and a 200,000+ sq. ft. cGMP facility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forge Biologics company profile →
Stealth Biotherapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapies targeting mitochondrial dysfunction, developing elamipretide to improve mitochondrial function for dry AMD, primary mitochondrial myopathy, Duchenne muscular dystrophy, and Barth syndrome, and SBT-272 for neurodegenerative diseases; conducts NuPOWER, TAZPOWER, and ReCLAIM-2 trials and offers an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stealth Biotherapeutics company profile →
AveXis
HQ: United States
Website
- Description: Provider of gene therapies specializing in the development and commercialization for patients and families affected by rare and life-threatening neurological genetic diseases; doing business as Novartis Gene Therapies, Inc. following Novartis’s 2018 acquisition and 2020 renaming.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AveXis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eidos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eidos Therapeutics
2.2 - Growth funds investing in similar companies to Eidos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eidos Therapeutics
4.2 - Public trading comparable groups for Eidos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →